Preparation method of medicinal 8-arm-polyethylene glycol-L-ascorbic acid acetate
Through the nucleophilic substitution reaction of 8-arm-polyethylene glycol and haloacetate and L-ascorbic acid esterification, combined with condensant and beating method, the medicinal 8-arm-polyethylene glycol-L-ascorbic acid acetic acid was solved by combining with condensation agent and beating method. The problem of impurities residue in ester preparation has achieved high purity and low cost industrial production, and improved the solubility and stability of the drug.
Patent Information
- Application Number
- CN202411082715.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-08
- Publication Date
- 2024-11-26
AI Technical Summary
The prior art lacks a method for preparing pharmaceutical 8-arm-polyethylene glycol-L-ascorbic acid acetate suitable for industrial production, which is difficult to meet the strict requirements of pharmaceutical customers for product quality, and there are impurity residue problems.
The nucleophilic substitution reaction was carried out with 8-arm-polyethylene glycol and halogenated acetate, and then esterified with L-ascorbic acid. The formation of rearranged by-products was reduced by using condensation agent and condensation activator, and the impurities were removed by beating to obtain high Purity of medicinal 8-arm-polyethylene glycol-L-ascorbic acid acetate.
It has achieved high purity (more than 99.5%), low cost, environmentally friendly preparation of 8-arm-polyethylene glycol-L-ascorbic acid acetate, comply with the standards of pharmaceutical enterprises, improves the solubility and stability of the drug, and reduces the Immunogenicity of peptides and proteins.
Smart Images

Figure CN119019672A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of pharmaceuticals, and particularly relates to a method for preparing medicinal 8-arm-polyethylene glycol-L-ascorbic acid acetate. Background Art
[0002] 8-arm-polyethylene glycol-L-ascorbic acid acetate is a multi-arm polyethylene glycol derivative with an L-ascorbic acid acetate group at each end of the eight arms connected to a trimerpentaerythritol, and a molecular weight of 2K to 40K. It has both the physiological activities of polyethylene glycol and vitamin C, and is a white or light yellow viscous liquid or waxy solid at room temperature, and can exist stably in the air. This product can increase the solubility and stability of drugs, reduce the immunogenicity of peptides and proteins, and inhibit the nonspecific binding of charged molecules on modified surfaces.
[0003] Medicinal 8-arm-polyethylene glycol-L-ascorbic acid acetate is a new type of pharmaceutical excipient of multi-arm polyethylene glycol derivatives, and there is no literature report on the relevant production technology. It can be used as an emulsifier, solubilizer, absorption promoter and antioxidant, etc. It has strong emulsification and solubilization ability, and can improve drug targeting. It has a large market application demand in the modern pharmaceutical field, especially in the development of innovative drug preparations at home and abroad. However, preparation customers have strict requirements on the content, acid value, moisture, drying loss, ignition residue, residual solvent, etc. of this excipient. Poor quality control will have an adverse effect on the efficacy of the preparation. Therefore, it is necessary to finely control the synthesis and refining process to reduce the residual impurities, improve product quality, and meet pharmaceutical needs.
[0004] Based on the above situation, there is an urgent need for a preparation method of medicinal 8-arm-polyethylene glycol-L-ascorbic acid acetate with excellent quality, high yield, low cost, environmental friendliness, simple operation and suitable for industrial production. Summary of the invention
[0005] The purpose of the present invention is to overcome the deficiencies of the prior art and provide a method for preparing medicinal 8-arm-polyethylene glycol-L-ascorbic acid acetate which has simple process, safe operation, low cost and product quality that meets the standards of pharmaceutical enterprises.
[0006] The technical solution of the present invention is summarized as follows:
[0007] Preparation method of medicinal 8-arm-polyethylene glycol-L-ascorbic acid acetate,
[0008] The synthetic route is:
[0009]
[0010] Among them: Ⅰ--8-arm-polyethylene glycol, Ⅱ--8-arm-polyethylene glycol acetate, Ⅲ--8-arm-polyethylene glycol acetic acid, Ⅳ--8-arm-polyethylene glycol-L-ascorbic acid acetate.
[0011] The following steps are involved:
[0012] (1) adding 8-arm-polyethylene glycol and a lower fatty alcohol into a reaction vessel, and then adding a strong alkaline catalyst, stirring evenly, reacting at 30-70° C. for 2-5 hours, wherein the molar ratio of 8-arm-polyethylene glycol to the strong alkaline catalyst is 1:12.8-32;
[0013] (2) adding dropwise a halogenated acetate equivalent to 2.5 to 6 times the molar number of 8-arm-polyethylene glycol to step (1), reacting at 30 to 70° C. for 4 to 9 hours to obtain a reaction solution containing 8-arm-polyethylene glycol acetate; then adding a 1N NaOH aqueous solution equivalent to 0.3 to 0.7 times the mass of a lower aliphatic alcohol at 10 to 30° C., stirring for 1 to 4 hours; adjusting the pH to 5.0 to 6.0 with 1N HCl to obtain a treated solution containing 8-arm-polyethylene glycol acetate;
[0014] (3) The treated solution containing 8-arm-polyethylene glycol acetic acid in step (2) is concentrated under reduced pressure to remove lower aliphatic alcohol to obtain a concentrated solution, and the concentrated solution is extracted twice with dichloromethane, the dichloromethane extracts are combined, and the concentrated solution is reduced pressure to a mass of the dichloromethane extract of 0.9 to 1.0 times the mass of 8-arm-polyethylene glycol, and n-hexane is added dropwise to the dichloromethane concentrate to precipitate solids, stirred and slurried, filtered, and the filter cake is dried to obtain 8-arm-polyethylene glycol acetic acid;
[0015] (4) adding the 8-arm-polyethylene glycol acetic acid and L-ascorbic acid obtained in step (3) to a reaction vessel at a molar ratio of 1:8.8 to 14.4, and then adding dichloromethane, stirring evenly, adding a condensation agent and a condensation activator at 0 to 10° C.; heating to 20 to 35° C., reacting for 3 to 6 hours, and obtaining a reaction solution, wherein the mass ratio of 8-arm-polyethylene glycol acetic acid to dichloromethane is 1:5.5 to 8;
[0016] (5) Concentrating the reaction solution obtained in step (4) under reduced pressure to 10% to 15% of the volume of the reaction solution, filtering to remove the filter cake, adding n-hexane dropwise to the filtrate to precipitate solids, stirring and beating to obtain a beating mixed solution;
[0017] (6) Filter the pulped mixed solution of step (5), wash the filter cake with n-hexane, and dry the filter cake to obtain medicinal 8-arm-polyethylene glycol-L-ascorbic acid acetate.
[0018] The HPLC and GPC spectra of the above 8-arm-polyethylene glycol-L-ascorbic acid acetate are as follows: Figure 1 , Figure 2 Shown; HPLC spectrum of the product prepared by the present invention.
[0019] Preferably, in step (1), the molecular weight of the 8-arm-polyethylene glycol is 2K to 40K, the strong alkaline catalyst is potassium methoxide, potassium ethoxide or potassium tert-butoxide; and the lower aliphatic alcohol is methanol, ethanol or tert-butanol.
[0020] Preferably, in step (1), the molar ratio of 8-arm-polyethylene glycol to the strong alkaline catalyst is 1:19.2-25.6, and the amount of lower aliphatic alcohol added is 5-8 times the mass of 8-arm-polyethylene glycol.
[0021] Preferably, in step (2), the halogenated acetate is methyl chloroacetate, ethyl chloroacetate, tert-butyl chloroacetate, methyl bromoacetate, ethyl bromoacetate or tert-butyl bromoacetate.
[0022] Preferably, the mass of dichloromethane used in the first extraction in step (3) is half the mass of the added 1N NaOH, and the mass of dichloromethane used in the second extraction is half the mass of dichloromethane used in the first extraction.
[0023] Preferably, the mass of n-hexane used for pulping in step (3) is 3 to 5 times the mass of 8-arm-polyethylene glycol;
[0024] Preferably, the molar ratio of 8-arm-polyethylene glycol acetic acid to L-ascorbic acid added in step (4) is 1:10.2-13.5.
[0025] Preferably, the condensation agent used in step (4) is dicyclohexylcarbodiimide, diisopropylcarbodiimide or 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide; and the condensation activator is 4-pyrrolidinopyridine, 4-dimethylaminopyridine or 1-hydroxybenzotriazole.
[0026] Preferably, in step (4), the molar ratio of 8-arm-polyethylene glycol acetic acid, condensation agent and condensation activator is 1:8-12:4.5-8.5.
[0027] Preferably, the mass of n-hexane used in the pulping in step (5) is 2.5 to 4 times the mass of 8-arm-polyethylene glycol acetic acid.
[0028] Preferably, the mass of n-hexane used for washing the filter cake in step (6) is 1 / 15 to 1 / 8 of the mass of n-hexane used for pulping in step (5).
[0029] 8-arm-polyethylene glycol-L-ascorbic acid acetate is a new type of pharmaceutical excipient, which is rarely reported at home and abroad, and no existing production technology can be found for the time being. The present invention uses 8-arm-polyethylene glycol and halogenated acetic acid ester as raw materials, and a nucleophilic substitution reaction occurs under the action of a strong alkaline catalyst to generate 8-arm-polyethylene glycol acetate; 8-arm-polyethylene glycol acetate undergoes an ester hydrolysis reaction under alkaline conditions to generate 8-arm-polyethylene glycol sodium acetate, and then adjusts the pH to acidity to obtain 8-arm-polyethylene glycol acetic acid; 8-arm-polyethylene glycol acetic acid and ascorbic acid are condensed into esters under the action of a condensation agent and a condensation activator to obtain 8-arm-polyethylene glycol-L-ascorbic acid acetate. This process has mild reaction conditions, fast reaction rate, few reaction by-products, and high reaction yield; due to the addition of a condensation activator, the generation of rearrangement by-products is reduced, and the purification difficulty is reduced; impurities such as unreacted raw materials and by-products in the reaction solution can be effectively removed by a pulping method. The obtained medicinal 8-arm-polyethylene glycol-L-ascorbic acid acetate has a content of more than 99.5%, an acid value of less than 0.10, a moisture content of less than 0.1%, and a drying loss of less than 0.1%, and the quality indicators all meet the pharmaceutical enterprise standards. It has both the physiological activities of polyethylene glycol and vitamin C, and is a white or light yellow viscous liquid or waxy solid at room temperature. The 8-arm-polyethylene glycol-L-ascorbic acid acetate can exist stably in the air, can increase the solubility and stability of drugs, reduce the immunogenicity of peptides and proteins, and inhibit the non-specific binding of charged molecules on the modified surface.
[0030] Advantages of the present invention:
[0031] 1. The method of the present invention uses 8-arm-polyethylene glycol as a raw material, first undergoes a nucleophilic substitution reaction with a halogenated acetate to obtain 8-arm-polyethylene glycol acetate, and then undergoes an esterification reaction with L-ascorbic acid to obtain medicinal 8-arm-polyethylene glycol-L-ascorbic acid acetate. The reaction conditions are mild, the reaction rate is fast, the reaction by-products are small, and the reaction yield is as high as 91% or more.
[0032] 2. The present invention uses dicyclohexylcarbodiimide, diisopropylcarbodiimide or 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide as a condensing agent, 4-pyrrolidinylpyridine, 4-dimethylaminopyridine or 1-hydroxybenzotriazole as a condensation activator, 8-arm-polyethylene glycol acetic acid first reacts with the condensing agent and the condensation activator to obtain 8-arm-polyethylene glycol acetic acid active ester, and then undergoes an esterification reaction with L-ascorbic acid under relatively mild reaction conditions to obtain 8-arm-polyethylene glycol-L-ascorbic acid acetate, which greatly reduces the reaction activation energy and improves the reaction rate; at the same time, due to the addition of the condensation activator, the generation of rearrangement by-products is greatly reduced, reducing the difficulty of purification;
[0033] 3. The present invention selects dichloromethane and n-hexane as purification solvents according to the difference in solubility, and can effectively remove impurities such as unreacted raw materials and by-products in the reaction solution through a pulping method, and the content of the obtained medicinal 8-arm-polyethylene glycol-L-ascorbic acid acetate is more than 99.5%;
[0034] 4. The medicinal 8-arm-polyethylene glycol-L-ascorbic acid acetate prepared by the method of the present invention has a content of more than 99.5%, an acid value of less than 0.10, a moisture content of less than 0.1%, and a drying loss of less than 0.1%, and the quality indicators all meet the pharmaceutical enterprise standards;
[0035] 5. The production process used in the present invention is simple to operate, the raw materials are readily available, the reaction conditions are mild, the yield is high, the operation is safe, the environment is friendly and pollution-free, and it is suitable for industrial production. BRIEF DESCRIPTION OF THE DRAWINGS
[0036] Figure 1 : HPLC spectrum of 8-arm-polyethylene glycol-L-ascorbic acid acetate
[0037] Figure 2 :GPC spectrum of 8-arm-polyethylene glycol-L-ascorbic acid acetate DETAILED DESCRIPTION
[0038] The present invention is further described in detail in the following examples, which should not be construed as limiting the claims of the present invention.
[0039] Example 1
[0040] The preparation method of medicinal 8-arm-polyethylene glycol-L-ascorbic acid acetate comprises the following steps:
[0041] (1) 8-arm-polyethylene glycol (molecular weight 5K) (1000 g, 0.2 mol) and 8000 g of ethanol were added to a reaction vessel, and potassium ethoxide (215.04 g, 2.56 mol) was added, stirred evenly, and reacted at 30° C. for 5 hours;
[0042] (2) Add ethyl bromoacetate (200.40 g, 1.2 mol) dropwise to step (1), react at 30°C for 9 hours to obtain a reaction solution containing 8-arm-polyethylene glycol acetate. Reduce the temperature to 10°C, add 2400 g of 1N NaOH aqueous solution, and stir for 4 hours. Adjust the pH to 5.0 with 1N HCl to obtain a treatment solution containing 8-arm-polyethylene glycol acetate;
[0043] (3) The treated solution containing 8-arm-polyethylene glycol acetic acid in step (2) was concentrated under reduced pressure to remove ethanol to obtain a concentrated solution, and the concentrated solution was extracted with 1200 g and 600 g of dichloromethane respectively, the dichloromethane extracts were combined, and the concentrated solution was concentrated under reduced pressure to obtain 1000 g of dichloromethane concentrated solution, 3000 g of n-hexane was added dropwise to the dichloromethane concentrated solution, stirred and slurried for 30 minutes, filtered, and the filter cake was dried to obtain 942.7 g of 8-arm-polyethylene glycol acetic acid;
[0044] (4) 8-Ar-polyethylene glycol acetic acid (942.7 g, 0.189 mol) and L-ascorbic acid (479.0 g, 2.72 mol) were added to a reaction vessel, and then 5184.9 g of dichloromethane was added, stirred evenly, cooled to 0° C., diisopropylcarbodiimide (285.8 g, 2.268 mol) and 4-pyrrolidinylpyridine (237.8 g, 1.607 mol) were added, and the temperature was raised to 20° C. and reacted for 6 hours;
[0045] (5) The reaction solution obtained in step (4) was concentrated to 10% of the volume of the reaction solution, the filter cake was removed by filtration, 2356.8 g of n-hexane was added dropwise to the filtrate to precipitate solids, and the mixture was stirred and slurried for 40 minutes to obtain a slurried mixed solution;
[0046] (6) Filter the pulped mixed solution of step (5), wash the filter cake with 294.6 g of n-hexane, and dry the filter cake to obtain medicinal 8-arm-polyethylene glycol-L-ascorbic acid acetate.
[0047] Sampling was performed for testing, and the samples were packaged and stored; 1172.86 g of medicinal 8-arm-polyethylene glycol-L-ascorbic acid acetate was obtained, and the purification yield was 91.63%. After testing, the quality indicators all met the pharmaceutical enterprise standards, as shown in Table 1.
[0048] Example 2
[0049] The preparation method of medicinal 8-arm-polyethylene glycol-L-ascorbic acid acetate comprises the following steps:
[0050] (1) 8-arm-polyethylene glycol (molecular weight 40K) (1000 g, 0.025 mol) and 5000 g of tert-butanol were added to a reaction vessel, and potassium tert-butoxide (89.6 g, 0.8 mol) was added, stirred evenly, and reacted at 70° C. for 2 hours;
[0051] (2) Add tert-butyl bromoacetate (12.19 g, 0.0625 mol) dropwise to step (1), react at 70°C for 4 hours to obtain a reaction solution containing 8-arm-polyethylene glycol acetate. Reduce the temperature to 30°C, add 3500 g of 1N NaOH aqueous solution, and stir for 1 hour. Adjust the pH to 6.0 with 1N HCl to obtain a treatment solution containing 8-arm-polyethylene glycol acetate;
[0052] (3) The treated solution containing 8-arm-polyethylene glycol acetic acid in step (2) was concentrated under reduced pressure to remove tert-butanol to obtain a concentrated solution, and the concentrated solution was extracted with 1750 g and 875 g of dichloromethane respectively, the dichloromethane extracts were combined, and the concentrated solution was concentrated under reduced pressure to obtain 900 g of dichloromethane concentrated solution, 5000 g of n-hexane was added dropwise to the dichloromethane concentrated solution, stirred and slurried for 45 minutes, filtered, and the filter cake was dried to obtain 947.1 g of 8-arm-polyethylene glycol acetic acid;
[0053] (4) 8-Ar-polyethylene glycol acetic acid (947.1 g, 0.0237 mol) and L-ascorbic acid (36.78 g, 0.209 mol) were added to the reaction vessel, and then 7576.8 g of dichloromethane was added, stirred evenly, cooled to 10°C, and dicyclohexylcarbodiimide (39.14 g, 0.190 mol) and 4-dimethylaminopyridine (13.05 g, 0.107 mol) were added dropwise. The temperature was raised to 35°C and the reaction was carried out for 3 hours;
[0054] (5) The reaction solution obtained in step (4) was concentrated to 15% of the volume of the reaction solution, the filter cake was removed by filtration, 3788.4 g of n-hexane was added dropwise to the filtrate to precipitate solids, and the mixture was stirred and slurried for 40 minutes to obtain a slurried mixed solution;
[0055] (6) Filter the pulped mixed solution of step (5), wash the filter cake with 252.6 g of n-hexane, and dry the filter cake to obtain medicinal 8-arm-polyethylene glycol-L-ascorbic acid acetate.
[0056] Sampling was performed for testing, and the samples were packaged and stored; 944.85 g of medicinal 8-arm-polyethylene glycol-L-ascorbic acid acetate was obtained, and the purification yield was 91.29%. After testing, the quality indicators all met the pharmaceutical enterprise standards, as shown in Table 1.
[0057] Example 3
[0058] The preparation method of medicinal 8-arm-polyethylene glycol-L-ascorbic acid acetate comprises the following steps:
[0059] (1) 8-arm-polyethylene glycol (molecular weight 10K) (1000 g, 0.1 mol) and 6000 g of methanol were added to a reaction vessel, and potassium methoxide (179.2 g, 2.56 mol) was added, stirred evenly, and reacted at 60° C. for 2.5 hours;
[0060] (2) Add methyl chloroacetate (32.5 g, 0.3 mol) dropwise to step (1), react at 60°C for 5 hours to obtain a reaction solution containing 8-arm-polyethylene glycol acetate. Reduce the temperature to 20°C, add 3000 g of 1N NaOH aqueous solution, and stir for 2 hours. Adjust the pH to 5.3 with 1N HCl to obtain a treated solution containing 8-arm-polyethylene glycol acetate;
[0061] (3) The treated solution containing 8-arm-polyethylene glycol acetic acid in step (2) was concentrated under reduced pressure to remove methanol to obtain a concentrated solution, and the concentrated solution was extracted with 1500 g and 750 g of dichloromethane respectively, the dichloromethane extracts were combined, and the concentrated solution was concentrated under reduced pressure to obtain 960 g of dichloromethane concentrated solution, 3500 g of n-hexane was added dropwise to the dichloromethane concentrated solution, stirred and slurried for 30 minutes, filtered, and the filter cake was dried to obtain 952.8 g of 8-arm-polyethylene glycol acetic acid;
[0062] (4) 8-Ar-polyethylene glycol acetic acid (952.8 g, 0.0953 mol) and L-ascorbic acid (171.08 g, 0.972 mol) were added to a reaction vessel, and then 7146 g (7.5 times) of dichloromethane were added, stirred evenly, cooled to 6° C., and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide (132.99 g, 0.858 mol) and 1-hydroxybenzotriazole (70.76 g, 0.524 mol) were added dropwise; the temperature was raised to 30° C. and the reaction was carried out for 4 hours;
[0063] (5) The reaction solution obtained in step (4) was concentrated to 15% of the volume of the reaction solution, the filter cake was removed by filtration, 2858.4 g of n-hexane was added dropwise to the filtrate to precipitate solids, and the mixture was stirred and slurried for 30 minutes to obtain a slurried mixed solution;
[0064] (6) Filter the pulped mixed solution of step (5), wash the filter cake with 285.8 g of n-hexane, and dry the filter cake to obtain medicinal 8-arm-polyethylene glycol-L-ascorbic acid acetate.
[0065] Sampling was performed for testing, and the samples were packaged and stored; 1053.13 g of medicinal 8-arm-polyethylene glycol-L-ascorbic acid acetate was obtained, and the purification yield was 92.38%. After testing, the quality indicators all met the pharmaceutical enterprise standards, as shown in Table 1.
[0066] Example 4
[0067] The preparation method of medicinal 8-arm-polyethylene glycol-L-ascorbic acid acetate comprises the following steps:
[0068] (1) 8-arm-polyethylene glycol (molecular weight 2K) (1000 g, 0.5 mol) and 7000 g of methanol were added to a reaction vessel, followed by potassium methoxide (672 g, 9.6 mol), stirred evenly, and reacted at 40° C. for 4.5 hours;
[0069] (2) Add methyl bromoacetate (382.5 g, 2.5 mol) dropwise to step (1), react at 40°C for 8 hours to obtain a reaction solution containing 8-arm-polyethylene glycol acetate. Reduce the temperature to 15°C, add 4200 g of 1N NaOH aqueous solution, and stir for 1.5 hours. Adjust the pH to 5.8 with 1N HCl to obtain a treated solution containing 8-arm-polyethylene glycol acetate;
[0070] (3) The treated solution containing 8-arm-polyethylene glycol acetic acid in step (2) was concentrated under reduced pressure to remove methanol to obtain a concentrated solution, and the concentrated solution was extracted with 2100 g and 1050 g of dichloromethane respectively, the dichloromethane extracts were combined, and the reduced pressure concentration was obtained to obtain 920 g of dichloromethane concentrated solution, 4300 g of n-hexane was added dropwise to the dichloromethane concentrated solution, stirred and slurried for 50 minutes, filtered, and the filter cake was dried to obtain 953.6 g of 8-arm-polyethylene glycol acetic acid;
[0071] (4) 8-Ar-polyethylene glycol acetic acid (953.6 g, 0.477 mol) and L-ascorbic acid (1048.96 g, 5.96 mol) were added to a reaction vessel, and then 5721.6 g of dichloromethane was added, stirred evenly, cooled to 5° C., and dicyclohexylcarbodiimide (1080.88 g, 5.247 mol) (11 times) and 1-hydroxybenzotriazole (483.03 g, 3.578 mol) (7.5 times) were added dropwise, and the temperature was raised to 25° C. and reacted for 5 hours;
[0072] (5) The reaction solution obtained in step (4) was concentrated to 15% of the volume of the reaction solution, the filter cake was removed by filtration, 3337.6 g of n-hexane was added dropwise to the filtrate to precipitate solids, and the mixture was stirred and slurried for 40 minutes to obtain a slurried mixed solution;
[0073] (6) Filter the pulped mixed solution of step (5), wash the filter cake with 278.1 g of n-hexane, and dry the filter cake to obtain medicinal 8-arm-polyethylene glycol-L-ascorbic acid acetate.
[0074] The samples were taken for testing and stored in aliquots. 1574.37 g of 8-arm-polyethylene glycol-L-ascorbic acid acetate was obtained, and the purification yield was 92.61%. After testing, the quality indicators all met the pharmaceutical enterprise standards, as shown in Table 1.
[0075] Example 5
[0076] The preparation method of medicinal 8-arm-polyethylene glycol-L-ascorbic acid acetate comprises the following steps:
[0077] (1) 8-arm-polyethylene glycol (molecular weight 20K) (1000 g, 0.05 mol) and 5000 g of ethanol were added to a reaction vessel, and potassium ethoxide (94.5 g, 1.125 mol) was added, stirred evenly, and reacted at 50° C. for 4 hours;
[0078] (2) Ethyl chloroacetate (24.5 g, 0.2 mol) was added dropwise to step (1), and the mixture was reacted at 50°C for 6 hours to obtain a reaction solution containing 8-arm-polyethylene glycol acetate. The temperature was lowered to 10°C, 2000 g of 1N NaOH aqueous solution was added, and the mixture was stirred for 3.5 hours. The pH was adjusted to 5.5 with 1N HCl to obtain a treatment solution containing 8-arm-polyethylene glycol acetate;
[0079] (3) The treated solution containing 8-arm-polyethylene glycol acetic acid in step (2) was concentrated under reduced pressure to remove ethanol to obtain a concentrated solution, and the concentrated solution was extracted with 1000 g and 500 g of dichloromethane respectively, the dichloromethane extracts were combined, and the concentrated solution was concentrated under reduced pressure to obtain 935 g of dichloromethane concentrated solution, 4000 g of n-hexane was added dropwise to the dichloromethane concentrated solution, stirred and slurried for 35 minutes, filtered, and the filter cake was dried to obtain 952.9 g of 8-arm-polyethylene glycol acetic acid;
[0080] (4) 8-Ar-polyethylene glycol acetic acid (952.9 g, 0.0476 mol) and L-ascorbic acid (104.72 g, 0.595 mol) were added to a reaction vessel, and then 6670.3 g of dichloromethane was added. The mixture was stirred evenly, cooled to 0°C, and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide (73.78 g, 0.476 mol) and 4-pyrrolidinylpyridine (42.33 g, 0.286 mol) were added dropwise.
[0081] Raise the temperature to 35°C and react for 3.5 hours;
[0082] (5) The reaction solution obtained in step (4) was concentrated to 15% of the volume of the reaction solution, the filter cake was removed by filtration, 3811.6 g of n-hexane was added dropwise to the filtrate to precipitate solids, and the mixture was stirred and slurried for 40 minutes to obtain a slurried mixed solution;
[0083] (6) Filter the pulped mixed solution of step (5), wash the filter cake with 254.1 g of n-hexane, and dry the filter cake to obtain medicinal 8-arm-polyethylene glycol-L-ascorbic acid acetate.
[0084] The samples were taken for testing and stored in aliquots. 1581.68 g of 8-arm-polyethylene glycol-L-ascorbic acid acetate was obtained, and the purification yield was 93.04%. After testing, the quality indicators all met the pharmaceutical enterprise standards, as shown in Table 1.
[0085] Example 6
[0086] The preparation method of medicinal 8-arm-polyethylene glycol-L-ascorbic acid acetate comprises the following steps:
[0087] (1) 8-arm-polyethylene glycol (molecular weight 40K) (1000 g, 0.025 mol) and 5000 g of tert-butanol were added to a reaction vessel, and potassium tert-butoxide (45.92 g, 0.41 mol) was added, stirred evenly, and reacted at 45° C. for 4.5 hours;
[0088] (2) Add tert-butyl chloroacetate (11.3 g, 0.075 mol) dropwise to step (1), react at 45°C for 7 hours to obtain a reaction solution containing 8-arm-polyethylene glycol acetate. Reduce the temperature to 25°C, add 3000 g of 1N NaOH aqueous solution, and stir for 2 hours. Adjust the pH to 5.2 with 1N HCl to obtain a treatment solution containing 8-arm-polyethylene glycol acetate;
[0089] (3) The treated solution containing 8-arm-polyethylene glycol acetic acid in step (2) was concentrated under reduced pressure to remove tert-butanol to obtain a concentrated solution, and the concentrated solution was extracted with 1500 g and 750 g of dichloromethane respectively, the dichloromethane extracts were combined, and the concentrated solution was concentrated under reduced pressure to obtain 910 g of dichloromethane concentrated solution, 3800 g of n-hexane was added dropwise to the dichloromethane concentrated solution, and the mixture was stirred and slurried for 55 minutes, filtered, and the filter cake was dried to obtain 949.6 g of 8-arm-polyethylene glycol acetic acid;
[0090] (4) 8-arm-polyethylene glycol acetic acid (949.6 g, 0.0237 mol) and L-ascorbic acid (45.94 g, 0.261 mol) (11.0 times) were added to the reaction vessel, and then 6172.4 g of dichloromethane was added, stirred evenly, cooled to 8° C., and dicyclohexylcarbodiimide (43.94 g, 0.213 mol) and 1-hydroxybenzotriazole (16.07 g, 0.119 mol) were added dropwise. The temperature was raised to 25° C. and the reaction was carried out for 4.5 hours;
[0091] (5) The reaction solution obtained in step (4) was concentrated to 15% of the volume of the reaction solution, the filter cake was removed by filtration, 3038.7 g of n-hexane was added dropwise to the filtrate to precipitate solids, and the mixture was stirred and slurried for 40 minutes to obtain a slurried mixed solution;
[0092] (6) Filter the pulped mixed solution of step (5), wash the filter cake with 276.2 g of n-hexane, and dry the filter cake to obtain medicinal 8-arm-polyethylene glycol-L-ascorbic acid acetate.
[0093] The samples were taken for testing and stored in aliquots. 961.00 g of 8-arm-polyethylene glycol-L-ascorbic acid acetate was obtained, and the purification yield was 92.85%. After testing, the quality indicators all met the pharmaceutical enterprise standards, as shown in Table 1.
[0094] Table 1 Pharmaceutical enterprise standards and test results of 8-arm-polyethylene glycol-L-ascorbic acid acetate
[0095]
[0096]
[0097] The technical solutions disclosed and proposed by the present invention can be realized by those skilled in the art by referring to the contents of this article and appropriately changing the conditions, routes and other links. Although the methods and preparation techniques of the present invention have been described through preferred embodiments, relevant technicians can obviously modify or re-combine the methods and technical routes described herein without departing from the content, spirit and scope of the present invention to realize the final preparation technology. It should be particularly noted that all similar substitutions and modifications are obvious to those skilled in the art, and they are all considered to be included in the spirit, scope and content of the present invention.
Claims
1. A method for preparing medicinal 8-arm-polyethylene glycol-L-ascorbic acid acetate, characterized in that The following steps are involved: (1) adding 8-arm-polyethylene glycol and a lower fatty alcohol into a reaction vessel, and then adding a strong alkaline catalyst, stirring evenly, reacting at 30-70° C. for 2-5 hours, wherein the molar ratio of 8-arm-polyethylene glycol to the strong alkaline catalyst is 1:12.8-32; (2) adding dropwise a halogenated acetate equivalent to 2.5 to 6 times the molar number of 8-arm-polyethylene glycol to step (1), reacting at 30 to 70° C. for 4 to 9 hours to obtain a reaction solution containing 8-arm-polyethylene glycol acetate; then adding a 1N NaOH aqueous solution equivalent to 0.3 to 0.7 times the mass of a lower aliphatic alcohol at 10 to 30° C., stirring for 1 to 4 hours; adjusting the pH to 5.0 to 6.0 with 1N HCl to obtain a treated solution containing 8-arm-polyethylene glycol acetate; (3) The treated solution containing 8-arm-polyethylene glycol acetic acid in step (2) is concentrated under reduced pressure to remove lower aliphatic alcohol to obtain a concentrated solution, and the concentrated solution is extracted twice with dichloromethane, the dichloromethane extracts are combined, and the concentrated solution is reduced pressure to a mass of the dichloromethane extract of 0.9 to 1.0 times the mass of 8-arm-polyethylene glycol, and n-hexane is added dropwise to the dichloromethane concentrate to precipitate solids, stirred and slurried, filtered, and the filter cake is dried to obtain 8-arm-polyethylene glycol acetic acid; (4) adding the 8-arm-polyethylene glycol acetic acid and L-ascorbic acid obtained in step (3) to a reaction vessel at a molar ratio of 1:8.8 to 14.4, and then adding dichloromethane, stirring evenly, adding a condensation agent and a condensation activator at 0 to 10° C.; heating to 20 to 35° C., reacting for 3 to 6 hours, and obtaining a reaction solution, wherein the mass ratio of 8-arm-polyethylene glycol acetic acid to dichloromethane is 1:5.5 to 8; (5) Concentrating the reaction solution obtained in step (4) under reduced pressure to 10% to 15% of the volume of the reaction solution, filtering to remove the filter cake, adding n-hexane dropwise to the filtrate to precipitate solids, stirring and beating to obtain a beating mixed solution; (6) Filter the pulped mixed solution of step (5), wash the filter cake with n-hexane, and dry the filter cake to obtain medicinal 8-arm-polyethylene glycol-L-ascorbic acid acetate.
2. The method for preparing the medicinal 8-arm-polyethylene glycol-L-ascorbic acid acetate as claimed in claim 1, characterized in that In step (1), the molecular weight of 8-arm-polyethylene glycol is 2K-40K, the strong alkaline catalyst is potassium methoxide, potassium ethoxide or potassium tert-butoxide, and the lower aliphatic alcohol is methanol, ethanol or tert-butanol.
3. The method for preparing the medicinal 8-arm-polyethylene glycol-L-ascorbic acid acetate as claimed in claim 1, characterized in that In step (1), the molar ratio of 8-arm-polyethylene glycol to the strong alkaline catalyst is 1:19.2-25.6, and the amount of lower aliphatic alcohol added is 5-8 times the mass of 8-arm-polyethylene glycol.
4. The method for preparing the medicinal 8-arm-polyethylene glycol-L-ascorbic acid acetate as claimed in claim 1, characterized in that In step (2), the halogenated acetate is methyl chloroacetate, ethyl chloroacetate, tert-butyl chloroacetate, methyl bromoacetate, ethyl bromoacetate or tert-butyl bromoacetate.
5. The method for preparing the medicinal 8-arm-polyethylene glycol-L-ascorbic acid acetate as claimed in claim 1, characterized in that The mass of dichloromethane used in the first extraction in step (3) is half of the mass of the added 1N NaOH, and the mass of dichloromethane used in the second extraction is half of the mass of dichloromethane used in the first extraction.
6. The method for preparing the medicinal 8-arm-polyethylene glycol-L-ascorbic acid acetate according to claim 1, characterized in that The mass of n-hexane used for pulping in step (3) is 3 to 5 times the mass of 8-arm-polyethylene glycol.
7. The method for preparing the medicinal 8-arm-polyethylene glycol-L-ascorbic acid acetate as claimed in claim 1, characterized in that The molar ratio of the 8-arm-polyethylene glycol acetic acid added in step (4) to L-ascorbic acid is 1:10.2-13.5; the condensing agent used is dicyclohexylcarbodiimide, diisopropylcarbodiimide or 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide, and the condensation activator is 4-pyrrolidinylpyridine, 4-dimethylaminopyridine or 1-hydroxybenzotriazole; the molar ratio of the 8-arm-polyethylene glycol acetic acid, the condensation agent and the condensation activator is 1:8-12:4.5-8.
5.
8. The method for preparing the medicinal 8-arm-polyethylene glycol-L-ascorbic acid acetate as claimed in claim 1, characterized in that The mass of n-hexane used in the pulping in step (5) is 2.5 to 4 times the mass of 8-arm-polyethylene glycol acetic acid.
9. The method for preparing the medicinal 8-arm-polyethylene glycol-L-ascorbic acid acetate as claimed in claim 1, characterized in that The mass of n-hexane used for cleaning the filter cake in step (6) is 1 / 15 to 1 / 8 of the mass of n-hexane used for pulping in step (5).
